Bone marrow-derived allogeneic ischemia tolerant mesenchymal stem cell therapy (Stemedica International)

N/A

Report date: 2023/01/12 15:29:04

Base Information

Drug NameBone marrow-derived allogeneic ischemia tolerant mesenchymal stem cell therapy (Stemedica International)
Drug Alias Namebone marrow-derived allogeneic itMSC therapy (iv, Alzheimer’s disease/dementia)bone marrow-derived allogeneic ischemia tolerant mesenchymal stem cell therapy (iv, Alzheimer’s disease/dementia)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapyCell and gene therapy > Cell therapy > Source of cells > Bone Marrow-derivedCell and gene therapy > Cell therapy > Donor > Allogeneic
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsST Elevation Myocardial InfarctionHeart FailureAlzheimer Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesStemedica International Sa
China Registration ClassN/A

Develop Information

Active CompaniesStemedica International SaStemedica Cell Technologies Inc
Inactive CompaniesCardioCell LLC
Active IndicationsAlzheimer Disease
Inactive IndicationsST Elevation Myocardial InfarctionHeart Failure

Other Information

ATC CodeN/A
Related LinksN/A